Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physcian’s perspective
| Autor: | Ahmed B. Bayoumy, F. Crouwel, Cjj Mulder, Azhar Ansari, N. K. H. de Boer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Mutual recognition procedure (MRP)
Remdesivir lcsh:RS1-441 Legislation Pharmacy Mexiletine Review Decentralized procedure (DCP) Pharmaceutical compounding Orphan drug lcsh:Pharmacy and materia medica 03 medical and health sciences 0302 clinical medicine Blueprint SARS-COV 2 Orphan drugs 030212 general & internal medicine Thioguanine Market Authorization Application (MAA) business.industry Centralized procedure (CP) Reference Member State (RMS) Health Policy Perspective (graphical) Drug repositioning lcsh:RM1-950 COVID-19 Public relations Venture capital Drug rediscovery Thalidomide Magistral compounding lcsh:Therapeutics. Pharmacology Drug development 030220 oncology & carcinogenesis Business Chenodeoxycholic acid Hydroxychloroquine |
| Zdroj: | Journal of Pharmaceutical Policy and Practice, Vol 13, Iss 1, Pp 1-9 (2020) Bayoumy, A B, De Boer, N K H, Ansari, A R, Crouwel, F & Mulder, C J J 2020, ' Unrealized potential of drug repositioning in europe during COVID-19 and beyond : A physcian's perspective ', Journal of pharmaceutical policy and practice, vol. 13, no. 1, 45 . https://doi.org/10.1186/s40545-020-00249-9 Journal of Pharmaceutical Policy and Practice |
| ISSN: | 2052-3211 |
| DOI: | 10.1186/s40545-020-00249-9 |
| Popis: | Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indications to existing drugs for lower costs compared to de novo drug development. Clinical research groups recognizing efficacy of these “old” drugs for a new indications often face an uphill struggle due to a lack of funding and support because of poor structural and regulatory support for clinical drug development. The current framework for drug repositioning allows “venture capital” companies to abuse loopholes in the legislation to gain long-term market authorization among with excessive high pricing. A new regulatory framework is needed to prevent abuse of the legislation and promote clinical investigator-driven drug repositioning. The COVID-19 pandemic has boosted funding and regulatory support for drug repositioning. The lessons learned from the COVID-19 pandemic should be implemented in a new clear blueprint for drug repositioning. This blueprint should guide clinicians through legislation for drug repositioning in the EU. This review summarizes the routes for registration and discusses the current state of drug repositioning in Europe. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |